-
Innovation Ranking
NewInnovation Ranking – SMA Solar Technology AG
SMA Solar Technology AG (SMA) is a renewable energy company. It develops, produces, and distributes photovoltaic inverters, choke coils, transformers, and monitoring and energy management systems for PV systems. It also offers intelligent energy management system and digital services, as well as solar power plant operation and maintenance. It serves customers in South America, Asia Pacific, North America, Europe, the Middle East, and Africa. Its R&D efforts focus on developing complete system solutions and digital business models. The company has...
-
Product Insights
Likelihood of Approval Analysis for Spinal Muscular Atrophy (SMA)
Overview How likely is it that the drugs in Spinal Muscular Atrophy (SMA) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is...
-
Product Insights
Spinal Muscular Atrophy (SMA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Muscular Atrophy (SMA) - Drugs In Development, 2023’, provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Likelihood of Approval Analysis for Motor Neuron Diseases
Overview How likely is it that the drugs in Motor Neuron Diseases will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Motor Neuron Diseases Overview Motor neuron diseases (MNDs) encompass a group...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Pancreatic Ductal Adenocarcinoma Drug Details: SLATE-001 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Non-Small Cell Lung Cancer Drug Details: SLATE-001...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Metastatic Colorectal Cancer Drug Details: SLATE-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-1019 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1019 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1019 in Colorectal Cancer Drug Details: CBP-1019 is under development for...